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The possibility of preserving human tissue separated from the body, from which to extract clinical information, even 
on large numbers of individuals with similar clinical conditions, represents a great opportunity for the progress 
of biomedicine. To date, it is virtually impossible to hypothesise all the future uses of such tissue. However, the 
decisive role of these biological materials in the understanding and resolution of questions regarding the origin and 
development of certain genetic diseases is well recognised.
The progress of genetic and biotechnological research has led to the proliferation of collections of biological 
materials by institutions called ‘biobanks’: repositories that store human biological samples, with or without linking 
them to genetic or clinical data.1 Usually biobanks are part of large public research centres, small hospitals and 
pharmaceutical companies. They conduct their activities following different, and not always standardised, storage 
and conservation protocols. Because of this enormous heterogeneity of structures, materials and methodologies, 
research biobanks have been subjected to profound ambiguity and fragmentation, as well as uncertainty in terms 
of regulation. This situation has encouraged discussion on the legal rules regarding their activities, particularly for 
the protection of donors’ rights.2-4
In the 21st century, the technological progress in automation and archival informatisation and the development 
of the World Wide Web boosted a radical revolution of biobanking. Marked changes have occurred in the context 
of the management of biological samples, particularly in regard to their transport and storage. However, progress 
has also been made in regard to the ethical and legal requirements necessary to ensure the privacy and safety of 
donors and the long-term availability of these materials. Collecting samples in a more accurate and ethical way may 
be a crucial contribution in the advancement of clinical and biomedical trials and, more generally, in the creation of 
more informative data sets. Such progress is also associated with a substantial increase in the production of data 
as a consequence of the collection of pathological, epidemiological, environmental and ethno-social information 
of the donors.
The collection of biological materials in compliance with ethical and legal standards could be seen as the main 
innovation of research biobanks. Firstly, collections of samples are virtually unusable today because of the lack 
of detail in the informed consent or because they were catalogued following inappropriate methods.5 Overcoming 
these issues represents one of the main enhancements for the development of modern and more structured 
biobanks.
biobanking: between politics and economics
Research biobanks often operate in very different contexts and, in many cases, their activities have become of 
primary interest to government agencies. In fact, the relationship between biobanks and politics is strengthening 
as many governments are increasingly interested in the efficiency and standardisation of ethical-legal frameworks 
for the sampling of biological materials. There is reciprocity between scientists and politicians: the collection of 
more, and extensively useable, human biological samples helps the former to conduct more accurate studies and 
guarantees the support of the latter regarding their political choices on scientific research. 
Biobanking has also revealed unprecedented business opportunities. In 2011, Global Industry Analysts released 
a global report on the biobank market, in which they predicted that the market in 2017 for high-quality human 
biological samples would be USD22.3 billion. Thus, the political and economic interests of biobanking are clear.
Scientific interests are obviously the first priority. There is no doubt that, globally, the development and growth of 
biobanks has exponentially increased opportunities for analysing and studying the collection of human biological 
samples and data extrapolated therefrom. This growth corresponds to an increase in research perspectives 
compared with those possible if the sampling and management of biological materials was still exclusively tied to 
the initiatives of individual research groups.1 In addition to these new opportunities, the rapid evolution of biobanking 
has also created new challenges and obstacles. Particularly, researchers have difficulty in accessing biobank 
resources. The propensity of these institutions to share their samples and data with the scientific community is 
a controversial subject which encompasses a double challenge: for researchers, gaining access to biological 
samples and data, and, for biobanks, finding a balance between the scientific interests of researchers and donors’ 
expectations. A first step towards a solution capable of satisfying both sides could be represented by a better and 
more flexible use of current forms of informed consent.6,7 However, the requirement of a consent form including a 
section ensuring the sustainability of a wide accessibility to samples and data does not solve the problem related 
to economic interests, which are often hidden and protected by the scientific aim itself.
Although biobanks have suddenly become more ‘open’, several bioethical issues related to the sharing procedures 
of biological resources have emerged. Starting from the drafting of informed consent, biobanks must take into 
account a number of ‘twists’ in the definition of the section concerning the handling of samples and data. They 
should meet the requirements of ethical committees. They should also clearly state the hypothetical future uses of 
their resources. Moreover, they should enable potential donors to make truly informed decisions.
Accessibility to biobank resources is generally conditional on the fulfilment of specific, often very compelling, 
requirements and seems to be related to three main aspects.8 The first aspect is the transparency between biobanks 
and applicants. Particularly, before allowing others to use their own materials, biobanks want to know the scientific 
aims of applicants. This request is strictly linked with specific sharing statements reported in the original consent 
form. It also provides a certain level of control by the biobanks regarding the scientific reliability and reputation 
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of applicants and their research groups, in order to reduce the risk of 
misuse of biobank resources. This is an ethical and technical approach 
to the management of scientific resources that can foster public trust in 
the work of these institutions, thus increasing willingness to participate 
in their activities.
Secondly, accessibility is related to the availability and origin of research 
funds. Biobanks seem to be more prone to collaborate with research 
groups that are publicly funded. This trend reflects the Organisation for 
Economic Co-operation and Development (OECD)’s recommendation in 
2007 for open access to scientific resources, in which these resources 
are defined as ‘public goods’. The OECD considers the sharing of these 
resources to be a means of enhancing public investment in scientific 
research. The availability of funds is a criterion adopted by biobanks 
in deciding whether or not to provide their resources to third parties. 
The presence of clauses directly linked to certain economic benefits for 
biobanks reveals their possible ‘second nature’ as institutions which also 
make a profit in providing bio-collection and storage services. However, 
it is not clear if this commercial nature operates as a sharing barrier, 
thereby lowering the risk of exploitation of their resources. As suggested 
by Caulfield and colleagues9, sample and data sharing is a practice 
that can be influenced, or even hindered, by the introduction of private 
funding and by collaboration with private groups. In fact, the latter could 
have economic expectations concerning the use of resources produced 
with their money. Consequently, these groups could have entered into 
agreements governing such collaborations by acting as sharing barriers.
Thirdly, accessibility is related to co-authorship. Some biobanks require 
recognition as co-authors on publications resulting from research based 
on the analysis of their samples and data. Other authors have highlighted 
this typical bad practice in the sharing behaviour of research groups.10-12 
Clearly, it contributes to the spread of a climate of mistrust and a lower 
propensity for cooperation within the scientific community.
These findings suggest that both economic and academic aspects are 
involved in determining ways to manage the exploitation of biological 
resources by biobanks currently operating on a global scale. However, 
biobanks can differ completely in goals and outcomes and diametrically 
opposed visions can coexist within the same biobank. We should also 
take into account that biobanks are regulated on the basis of both national 
and international rules (such as the Transatlantic Trade and Investment 
Partnership bilateral agreement between the USA and the European 
Union), which sometimes hinder harmonisation, with consequences 
that may affect national health services and, more generally, biomedical 
research. 
looking to tomorrow
The availability of high-quality samples, accompanied by detailed 
metadata, will be the decisive push for the discovery of previously 
unknown biomarkers, thus facilitating the definition of new and innovative 
therapies.13,14 The only way to increase the number and variety of human 
biological samples is to increase the ‘source of tissues’ and the efficiency 
of their provision.5 The future of biobanks will depend, first and foremost, 
on their ability to respond to this increased demand. However, biobanks 
will only be able to overcome this challenge if they can also significantly 
reduce sampling and distribution costs. If we look at biobanking from 
this point of view, its tomorrow will be a matter of business in which only 
those institutions that will be able to operate efficiently and sustainably 
will remain and compete.
In this scenario, biobank networks can be seen as the most promising 
strategy to try to facilitate accessibility to samples and their findability. 
In the USA, the Cooperative Human Tissue Network (CHTN) is a 
‘generalised biobank’ capable of collecting any kind of human samples 
for any biomedical research. In Europe, the Biobanking and BioMolecular 
Resources Research Infrastructure (BBMRI-ERIC) has been in operation 
since 2013 and is probably the world’s largest biobank network. 
BBMRI-ERIC provides access to human biological samples that are 
considered raw materials needed for the advancement and development 
of biomedicine in Europe. Consortia such as CHTN and BBMRI-ERIC 
are increasingly essential, particularly for those research groups that do 
not have enough funding and human capacity to maintain an efficient 
biobank. However, while these networks are organised and equipped 
with impressive numbers of high-quality samples, obviously they will not 
actually meet all the needs of research groups. This is because certain 
studies require a specific type of biological material and a large number 
of samples collected from a specific population. Thus, there will still be 
room for local and small biobanks.
In the near future, another aspect that will affect biobanks’ choices in 
collecting samples, particularly regarding the type of tissue and the 
sample size, will be the so-called ‘post-genomic revolution’. It will force 
researchers around the world towards increasingly specific sample 
requirements that will reverberate in the activity of biobanks, particularly 
in the need to develop more coordinated collections to satisfy specific 
scientific issues. De Souza and Greenspan15 point out that this process 
has already begun, as evidenced by the advent of population biobanks, 
as well as biobanks which collect only DNA or focus their activity on a 
single pathology.
We can conclude that the future of biobanking is double-edged. Bright 
and, at the same time, full of obstacles. First of all, its evolution will 
depend on addressing some of the unsolved problems preventing the 
full exploitation of resources, mostly in regard to the lack of shared 
standards for collecting, cataloguing and managing samples. Another 
issue is the long-term sustainability of these institutions. The scientific 
community needs efficient biobanks to support long-term studies. 
However, this aspect would require a separate study of the critical points 
linked with the maintenance of such institutions and the efficiency of their 
activities in supporting actively and dynamically the research enterprise. 
Biobanks will also have to face the question of open access to their 
resources. As discussed above, there are still barriers to the sharing of 
samples and data between biobanks and researchers. The fact that the 
scientific community is fully aware of the importance of sharing does not 
necessarily mean that these barriers are harmful and unfair and that they 
should not exist. In fact, some of them play an important role, because 
they exist to guarantee the fundamental rights of donors and prevent the 
misuse of biological materials. Thus, respect for donors’ rights should 
always be given consideration in trying to overcome these barriers, not 
as a means to unify all the procedures for accessing biological resources 
but to find a definition of a globally recognised operating standard.
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